Deutsche Bank’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.21M | Buy |
239,687
+33,317
| +16% | +$169K | ﹤0.01% | 1967 |
|
|
2025
Q1 | $1.09M | Sell |
206,370
-11,353
| -5% | -$60.1K | ﹤0.01% | 2080 |
|
|
2024
Q4 | $1.47M | Buy |
217,723
+75,994
| +54% | +$514K | ﹤0.01% | 2004 |
|
|
2024
Q3 | $934K | Buy |
141,729
+31,852
| +29% | +$210K | ﹤0.01% | 2109 |
|
|
2024
Q2 | $824K | Buy |
109,877
+28,795
| +36% | +$216K | ﹤0.01% | 2065 |
|
|
2024
Q1 | $808K | Buy |
81,082
+2,735
| +3% | +$27.3K | ﹤0.01% | 2081 |
|
|
2023
Q4 | $773K | Buy |
78,347
+18,659
| +31% | +$184K | ﹤0.01% | 2125 |
|
|
2023
Q3 | $457K | Buy |
59,688
+7,973
| +15% | +$61K | ﹤0.01% | 2203 |
|
|
2023
Q2 | $386K | Sell |
51,715
-36,945
| -42% | -$276K | ﹤0.01% | 2495 |
|
|
2023
Q1 | $591K | Buy |
88,660
+17,687
| +25% | +$118K | ﹤0.01% | 2393 |
|
|
2022
Q4 | $547K | Buy |
70,973
+12,903
| +22% | +$99.5K | ﹤0.01% | 2396 |
|
|
2022
Q3 | $618K | Sell |
58,070
-6,248
| -10% | -$66.5K | ﹤0.01% | 2256 |
|
|
2022
Q2 | $523K | Sell |
64,318
-1,481
| -2% | -$12K | ﹤0.01% | 2557 |
|
|
2022
Q1 | $471K | Sell |
65,799
-7,002
| -10% | -$50.1K | ﹤0.01% | 2773 |
|
|
2021
Q4 | $1.25M | Buy |
72,801
+56,039
| +334% | +$960K | ﹤0.01% | 2292 |
|
|
2021
Q3 | $385K | Buy |
16,762
+3,640
| +28% | +$83.6K | ﹤0.01% | 3184 |
|
|
2021
Q2 | $479K | Buy |
+13,122
| New | +$479K | ﹤0.01% | 3235 |
|